Communiqués CombiGene AB

Actions

LARK

SE0016101935

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 14/07/2026			Varia. 5j.	Varia. 1 janv.
2,350 ^SEK	+3,07%		+5,38%	+3,98%

21/04	Larkberget va procéder à une augmentation de capital avec maintien du droit préférentiel de souscription de 14,9 millions SEK	RE
17/04	Larkberget : l'actif net réévalué s'établit à 3,04 SEK par action	RE

Communiqués

14/02/25	CombiGene : Year end report January December 2024 CombiGene AB (Publ)	PU
14/02/25	Year-end report January-December 2024 CombiGene AB (Publ)	AQ
28/01/25	Discontinuation of research activities	AQ
09/01/25	CombiGene initiates restructuring as part of strategic review to maximize shareholder value	AQ
17/12/24	CombiGene AB (publ): Nominating committee	AQ
10/12/24	Bulletin from the Extraordinary General Meeting of CombiGene AB (publ)	AQ
02/12/24	CombiGene conducts Extraordinary General Meeting	AQ
14/11/24	Shareholders’ proposal for election of Board of Directors	AQ
11/11/24	CombiGene: Strategic consequences after CG01	AQ
08/11/24	Interim report January – September 2024 for CombiGene AB (publ)	AQ
01/11/24	NOTICE OF EXTRAORDINARY GENERAL MEETING IN COMBIGENE AB (PUBL)	AQ
31/10/24	The Board of Directors of CombiGene has received proposals from the Company’s largest shareholder for the Extraordinary General Meeting intended to be convened	AQ
30/10/24	BioStock: CombiGene implements cost savings	AQ
29/10/24	CombiGene: New priorities after strategic decision	AQ
28/10/24	CombiGene Initiates Measures to Extend Liquidity Horizon by Sharpening Strategic Focus on Gene Therapy, Prioritizing Pipeline Assets, and Implementing a Cost Reduction Program	AQ
30/09/24	CombiGene announces new preclinical research results in the epilepsy project	AQ
23/09/24	CombiGene's CEO to BioStock: "I am looking forward to meeting more potential partners"	AQ
29/08/24	CombiGene: Advancements according to plan	AQ
26/08/24	BioStock: Continued focus on new licensing deals for CombiGene	AQ
23/08/24	Interim report January – June 2024 for CombiGene AB (publ)	AQ
26/06/24	BioStock: CombiGene positive to new license agreement for CG01	AQ
25/06/24	Västra Hamnen publishes initial analysis of CombiGene	AQ
24/06/24	CombiGene enters into a license agreement with Spark for the epilepsy project CG01	AQ
20/06/24	CombiGene: Preclinical experts in gene therapy	AQ
14/06/24	CombiGene selects Västra Hamnen Corporate Finance as new Certified Adviser	AQ